Ondansetron Injection, USP is indicated for prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin, and for prevention of postoperative nausea and/or vomiting.
The injection features the company’s PreventIV Measures packaging and labeling, designed to help reduce medication errors.
The US market for Ondansetron Injection, USP for the 12 months ending June 2012 is approximated $49m, according to IMS data.